Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to establish an eye injury registry to assess the mechanisms and outcomes of significant eye injuries occurring in Canada. The epidemiologic data will determine where public health strategies should be directed to prevent future eye injuries.


Clinical Trial Description

Currently there is no established database or recording system of eye injuries occurring in Canada. Estimates place the figure at approximately 100000 significant eye injuries occurring in our country every year. This represents a large public health and long-term disability challenge. Lost productivity of working-age individuals with vision loss amounts to $4.4 billion annually in Canada, part of which is due to eye injury. By recording the types, locations, and outcomes of significant eye injuries, it is hoped improved public health strategies may be established to prevent further ones. The need for such a database has been recognized by the Ivey Eye Institute, the Canadian National Institute for the Blind (CNIB) and the Canadian Ophthalmological Society (COS).

The United States Eye Injury Registry (USEIR) has been in existence for greater than 20 years. Through their database they have recorded thousands of eye injuries which has led to public health interventions through their various ocular societies. They have also established a standardized reporting system and ocular trauma score which has improved diagnosis and prognosis of eye injuries. This system has been used in many countries as a standardized reporting scheme for eye injuries.

It is hoped that through a pilot recording system established in London a framework for a national reporting system will develop. The objective is to use the standardized reporting system of the USEIR to report Canadian eye injuries.

The time frame for outcome measures will be 6 months. The patients will be followed along for this amount of time to assess there visual outcomes. No further follow up after 6 months will be undertaken for the purpose of the registry.

The hypothesis is that by recording the type and outcome of eye injuries, a better understanding of mechanisms and location of these injuries in Canada will occur. Subsequent public health interventions can then be made in conjunction with the CNIB and COS to improve eye health in Canada. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01490593
Study type Observational
Source Lawson Health Research Institute
Contact
Status Completed
Phase N/A
Start date March 2, 2011
Completion date January 31, 2015

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04521283 - Visual Outcome of Traumatic Posterior Segment Complications
Not yet recruiting NCT03908515 - Multi-center Clinical Observation of FCVB in Guangdong Province
Completed NCT05771467 - Evaluation of Retinal Microvascular Change That May Develop in Patients After Open Globe İnjury With Optical Coherence Tomography (OCTA)
Completed NCT00129077 - Does the Use of a Moisture Chamber Decrease the Incidence of Corneal Abrasions in Critically Ill Pediatric Patients? N/A
Recruiting NCT03706560 - Professional Consequences of Ocular Trauma Hospitalized at the Hospital Centre of Clermont-Ferrand
Not yet recruiting NCT05164588 - A Prospective Study of Traumatic Eye Injuries in the Period From January 2022 to June 2022 in Sohag University Hospitals
Completed NCT02638025 - Anterior Segment Spectral-domain Optical Coherence Tomography in Patients With Closed Globe Injury N/A
Completed NCT04595357 - "Iris Shelf" Technique for Intraocular Foreign Bodies Removal
Completed NCT04837534 - Improving the Follow up Rate for Pediatric Patients N/A
Not yet recruiting NCT06174415 - An Exploratory Study of Visual Function Rehabilitation in Patients With Ocular Trauma N/A
Completed NCT00598299 - Comparison of the Effects on Promoting Corneal Epithelial Wound Healing Between Human Auto-Serum and Cord Blood Serum N/A
Terminated NCT00211367 - Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg) Phase 2